CellaVision AB

CEVI · Nasdaq Stockholm · Healthcare

168.60SEK −2.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: −0.1%

Performance

1 month

+3.7%

1 year

−0.1%

3 years, per year

+4.0%

5 years, per year

−14.3%

Largest fall, 3 years

−74.6%

Below the peak now

−63.5%

Volatility, 1 year

41.9%

Return with dividends reinvested.

Key figures

P/E

30.1

P/B

4.4

Dividend yield

1.6%

Return on equity

+14.6%

Net margin

+17.5%

Market value

400 m USD

Quality, value and trend

Where CellaVision stands against every Nordic stock today. 100 is best.

Quality99

Profitability and a sound balance sheet over time. Better than 99% of Nordic stocks.

Value20

The price measured against earnings, assets and cash flow. Better than 20% of Nordic stocks.

Trend76

The price development over the past year. Better than 76% of Nordic stocks.

Combined80

Quality, value and trend together. Better than 80% of Nordic stocks.

About CellaVision

CellaVision AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 250 employees.

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis